Oracle Corporation (ORCL)

The panel's take

Verdict: WAIT · Conviction: HIGH · Last price: 150.52

This is a BUY vs WAIT split, not BUY vs SELL. Five of six voices are non-bullish, and four of those five (technical scout, fundamental scout, The GARP Operator, The Asymmetric Bargainer) explicitly say "good business, wrong price/timing" — they want ORCL, just not here. The lone business-objection voice is The Moat Compounder (leverage as dealbreaker), but even he says he'd buy below $120. The structure is unambiguous: the business is not in fundamental dispute; the entry price and absence of a bottoming catalyst are. Per Step B rule: BUY vs WAIT split synthesizes to WAIT.

Key levels

What legendary investors think

We ran Oracle Corporation past a panel of 5 legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Can Oracle deleverage fast enough to turn its genuine AI-infrastructure tailwind into equity value before the $135B debt load and $20B equity dilution punish shareholders who bought at $150?

The bottom line

• Line in the sand: A weekly close below the EMA200 at $149 would confirm deepening Stage 4 and open a path to the $120–122 zone where The Moat Compounder and The Asymmetric Bargainer both see genuine margin of safety.
• Trigger to turn bullish: A monthly close above the EMA20 at $171.76 with improving weekly MACD would signal the 56% drawdown is stalling, flipping The GARP Operator and The Intrinsic-Value Modeler from neutral to constructive.
• Catalyst to watch: The FY2027 $20B equity ATM program's pricing and size will reveal whether management can raise capital without cratering the stock — any increase in the planned dilution would validate The Forensic Skeptic's worst-case path.
• Debt milestone: A credible plan to reduce net debt below $100B within two years, or a credit-rating-agency upgrade on improving leverage metrics, would remove the single largest objection shared across all five non-bullish voices.

The panel's take

Verdict: SELL · Conviction: LOW · Last price: 146.47 · Changed from WAIT

Panel: 0 Bullish · 2 Neutral · 3 Bearish → SELL

What changed since 2026-08-15:

• Price: 150.52 → 146.47 (-2.69%)
• Panel: 0 of 5 → 0 of 5 now Bullish — composition also changed: added The Activist Catalyst; removed The Moat Compounder
• Trigger: A weekly close above the weekly EMA200 ($148.82) and the weekly EMA20 ($157.44) would break the immediate Stage 4 downtrend — until then, every rally is a sale into resistance. A break below $139.90 (monthly EMA50) confirms full Stage 4 on the monthly timeframe and opens the path to $120–122.
• Verdict: WAIT → SELL

The prior WAIT verdict at $150.52 held because the panel saw a good business trapped in a bad chart but without enough technical damage to justify a SELL. Since then, the stock has slipped another 2.7% and, more importantly, The Moat Compounder was replaced by The Activist Catalyst, whose framework treats negative FCF and insider selling as categorical disqualifiers rather than negotiable risks. That shift, combined with the Forensic Skeptic and Intrinsic-Value Modeler now explicitly linking their bear cases to the same $23.7B cash burn, tipped the arithmetic from WAIT to SELL even though no single archetype changed its own signal.

Three of five voices are Bearish; the two Neutrals both acknowledge the stock is a good business at an attractive valuation but refuse to commit until the technical picture improves — a PRICE/TIMING objection, not a defence of the business. With zero Bullish votes and the Bears outnumbering the rest 3–2, SELL is the arithmetic read of the panel. The As-of price of $146.47 sits below the weekly EMA200 ($148.82) and just above the critical monthly EMA50 ($139.90); that thin sliver is the only thing keeping a full Stage 4 collapse at bay, so the risk of a break toward $120 dominates the near-term calculus.

Key levels

Key resistance clusters tightly overhead: the weekly EMA200 at $148.82 is the first gate on any bounce, followed by the weekly EMA20 at $157.44 and the cluster at $163.98–$173.49 where the monthly 78.6% and 61.8% Fibonacci retracements overlap with the monthly EMA20. On the downside, key support sits at the monthly EMA50 at $139.90 — the last line before an open-air drop to the $120.14 weekly volume POC (historical accumulation zone) and the weekly swing low at $114.50. The analyst consensus target of $246.43 implies 68% upside, but that target sits above the $191.38 monthly volume POC, which is now a historical resistance zone.

What legendary investors think

We ran Oracle Corporation past a panel of 5 legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Does the capex cycle peak soon enough to turn free cash flow positive before the debt load and competitive pressure force a break below $139.90 — or is the current price already discounting a capex normalization that may never arrive?

The bottom line

• Line in the sand: A weekly close above the weekly EMA200 at $148.82 would break the immediate Stage 4 downtrend and force a re-evaluation of the bear case.
• Breakdown trigger: A close below the monthly EMA50 at $139.90 confirms full Stage 4 on the monthly timeframe and opens the path to $120–122.
• Capex inflection to watch: The first quarter in which capex falls below 100% of operating cash flow would change the FCF narrative overnight; the September 2026 earnings print is the next opportunity for that signal.
• Insider pivot: Insider buying by Ellison, Catz, or another senior executive would neutralize the Vice Chairman’s June sale — silence or further selling reinforces the bear case.